/
RNA
$12.84+$0.51 (+4.14%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$208.2M
17M shares
52-week range
$11.13 – $73.06
3% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-5.32
Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
www.aviditybiosciences.com- Employees
- 391
- IPO / List date
- Feb 27, 2026
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds RNA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in RNA as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded RNA yet.
